Medtronic Plc (MDT) delivered a solid second-quarter performance on Tuesday that has Wall Street rethinking its stance on the medical device giant. The company's Q2 2026 results came in ahead of expectations across the board, prompting a wave of analyst upgrades and higher price targets.

The numbers tell a compelling story. Revenue hit $8.96 billion, topping the consensus estimate of $8.87 billion and representing a 6.6% year-over-year increase. Organic growth clocked in at 5.5%, while adjusted earnings of $1.36 per share beat the $1.31 forecast. Not bad for a company that size.

"…Overall, procedure volumes and our end markets are robust, and we're executing well across the business," said Geoff Martha, Medtronic chairman and CEO.

The strong quarter gave management enough confidence to boost guidance for the full fiscal year 2026. Medtronic now expects organic revenue growth of 5.5%, up from its previous 5% target. The company also tweaked its adjusted earnings forecast to $5.62-$5.66 per share, compared to the prior range of $5.60-$5.66 and consensus expectations of $5.63.

There's a caveat worth noting: the guidance still includes a potential $185 million hit from tariffs, unchanged from previous estimates. Strip out that tariff headwind, and the company is projecting adjusted earnings growth of approximately 4.5% for fiscal 2026.

Despite the upbeat results, Medtronic shares dipped 0.1% to $100.78 on Wednesday. The market works in mysterious ways.

The real action came from the analyst community, where six firms adjusted their outlooks on the stock:

• Goldman Sachs analyst David Roman made the boldest move, upgrading Medtronic from Sell to Neutral and dramatically raising the price target from $81 to $111.
• Baird analyst David Rescott kept a Neutral rating but lifted the price target from $103 to $109.
• Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and bumped the target from $100 to $114.
• UBS analyst Danielle Antalffy stuck with a Neutral rating while increasing the price target from $95 to $102.
• RBC Capital analyst Shagun Singh held an Outperform rating and raised the target from $111 to $118.
• Morgan Stanley analyst Cecilia Furlong maintained an Overweight rating and lifted the price target from $107 to $117.

The breadth of positive revisions suggests analysts see genuine momentum in Medtronic's business, with procedure volumes staying healthy and execution improving across segments.